Related Experiment Videos
[A patient with thromboangiitis obliterans]
Jan Erik Otterstad1, Odd Strøm
1Medisinsk avdeling Sentralsykehuset i Vestfold 3116 Tønsberg. j-otte@online.no
Summary
Thromboangiitis obliterans (Buerger's disease) is a rare vascular condition. Complete smoking cessation is the only proven treatment, though long-term anticoagulation and sympathectomy showed symptomatic benefit in a long-term case study.
Area of Science:
- Vascular Surgery
- Cardiology
- Rheumatology
Background:
- Thromboangiitis obliterans (Buerger's disease) involves inflammatory thrombi in small and medium-sized vessels, distinct from arteriosclerosis.
- Diagnostic criteria include distal ischemia, absence of other conditions, age under 45, and smoking history.
Observation:
- A case study of a patient diagnosed with Buerger's disease at age 31 in 1953.
- The patient underwent lumbar sympathectomy and received anticoagulants for 48 years.
- A toe amputation was performed, but the patient remained free of cardiovascular events until age 80.
Findings:
- The incidence of Buerger's disease has significantly decreased over the past 50 years, with the cause remaining unknown.
- Complete tobacco cessation is the only definitively proven treatment for Buerger's disease.
- The long-term efficacy of sympathectomy and anticoagulation remains unproven, despite symptomatic improvement in this case.
Implications:
- Highlights the critical role of smoking cessation in managing Buerger's disease.
- Suggests potential long-term symptomatic benefits of interventions like sympathectomy and anticoagulation, warranting further investigation.
- Underscores the declining incidence of Buerger's disease and the need to understand the underlying reasons.